Arrowhead Pharmaceuticals (ARWR) Chardan's 8th Annual Genetic Medicines Conference summary

Business overview and strategic focus

• Expanded RNAi platform to target multiple tissue types beyond the liver, enabling treatment of previously undruggable diseases.

• Diversified and growing pipeline requires prioritization, with significant resources allocated to lead asset plozasiran.

• Commercialization efforts are underway, with plans to launch plozasiran next year and build out a commercial organization.

• Presented and published positive data on cardiometabolic pipeline, especially plozasiran.

• Shift in focus from early-stage platform development to late-stage development and commercialization.

Financial strategy and capital allocation

• Raised approximately $1 billion from business development, $700–750 million from equity, $400 million from debt, and $300 million from royalty monetization over the past 6–7 years.

• Strategy emphasizes diversified capital sources, with business development as the largest contributor.

• Ongoing business development deals aim to bring in cash and reduce future R&D spend by partnering programs.

• Anticipates reaching cash flow positivity in the coming years, reducing reliance on external capital.

Pipeline execution and market positioning

• Recognizes undervaluation despite a broad and deep pipeline, attributing it to the complexity of the portfolio and communication challenges.

• Execution and clear messaging around near-term value drivers, especially plozasiran, are key priorities.

• Early-stage programs have generated compelling data with significant commercial and clinical potential.